- Home
- ILLR vs SLN Comparison
ILLR vs SLN Comparison
Compare ILLR & SLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- SLN
- Stock Information
- Founded
- ILLR 2015
- SLN 1994
- Country
- ILLR United States
- SLN United Kingdom
- Employees
- ILLR N/A
- SLN N/A
- Industry
- ILLR Investment Managers
- SLN Biotechnology: Pharmaceutical Preparations
- Sector
- ILLR Finance
- SLN Health Care
- Exchange
- ILLR Nasdaq
- SLN Nasdaq
- Market Cap
- ILLR 369.3M
- SLN 352.2M
- IPO Year
- ILLR N/A
- SLN N/A
- Fundamental
- Price
- ILLR $1.90
- SLN $5.56
- Analyst Decision
- ILLR
- SLN Strong Buy
- Analyst Count
- ILLR 0
- SLN 4
- Target Price
- ILLR N/A
- SLN $61.50
- AVG Volume (30 Days)
- ILLR 947.0K
- SLN 439.4K
- Earning Date
- ILLR 02-15-2025
- SLN 03-11-2025
- Dividend Yield
- ILLR N/A
- SLN N/A
- EPS Growth
- ILLR N/A
- SLN N/A
- EPS
- ILLR N/A
- SLN N/A
- Revenue
- ILLR $45,244,000.00
- SLN $21,773,221.00
- Revenue This Year
- ILLR N/A
- SLN N/A
- Revenue Next Year
- ILLR N/A
- SLN $104.98
- P/E Ratio
- ILLR N/A
- SLN N/A
- Revenue Growth
- ILLR N/A
- SLN N/A
- 52 Week Low
- ILLR $0.66
- SLN $4.82
- 52 Week High
- ILLR $8.86
- SLN $27.72
- Technical
- Relative Strength Index (RSI)
- ILLR N/A
- SLN 33.35
- Support Level
- ILLR N/A
- SLN $4.82
- Resistance Level
- ILLR N/A
- SLN $7.87
- Average True Range (ATR)
- ILLR 0.00
- SLN 0.65
- MACD
- ILLR 0.00
- SLN 0.02
- Stochastic Oscillator
- ILLR 0.00
- SLN 22.70
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About SLN Silence Therapeutics Plc American Depository Share
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.